Yeast-based pharmacogenomics: An IFOM/IEO project to optimize the objectives of Phase I trials

被引：0
|
作者：
Spitaleri, Gianluca
Ferrari, Elisa
Foiani, Marco
Toffalorio, Francesca
Delmonte, Angelo
de Pas, Tommaso M.
Noberasco, Cristina
Catania, Chiara
de Braud, Filippo
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-2193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2193
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
    Xu, Jin
    Zhang, Dapeng
    Mu, Rongji
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [32] Risk assessment based on the Risk Index for Serious Adverse Events (SAEs) in Phase I trials
    Koganemaru, Sigehiro
    Kuboki, Yasutoshi
    Shitara, Kohei
    Nomura, Shogo
    Takahashi, Hideaki
    Naito, Yoichi
    Sakai, Takahiro
    Kimura, Yukie
    Yoh, Kiyotaka
    Doi, Toshihiko
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [33] Evolving considerations in the design and interpretation of phase I trials investigating gemcitabine based chemoradiotherapy regimens
    McGinn, CJ
    [J]. CANCER JOURNAL, 2002, 8 (03): : 239 - 241
  • [34] A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
    Jin Xu
    Dapeng Zhang
    Rongji Mu
    [J]. BMC Medical Research Methodology, 22
  • [35] Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
    Simmet, V.
    Eberst, L.
    Marabelle, A.
    Cassier, P. A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (11) : 1751 - 1759
  • [36] A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes
    Lin, Ruitao
    Thall, Peter F.
    Yuan, Ying
    [J]. BAYESIAN ANALYSIS, 2021, 16 (01): : 179 - 202
  • [37] Comparison of model-based dose escalation design with rule-based design of phase I oncology trials
    Shimomura, A.
    Ebata, T.
    Koyama, T.
    Iwasa, S.
    Kondo, S.
    Kitano, S.
    Yonemori, K.
    Fujiwara, Y.
    Shimizu, T.
    Yamamoto, N.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [38] Evolution of phase 1 clinical trials for head and neck cancer patients based on the experience of a dedicated phase I Unit.
    Rojas, Katerin
    Hernando, Alberto
    Assaf, Juan
    Garcia, Eduardo
    Vieito, Maria
    Galvao, Vladimir
    Saavedra, Omar
    Alonso, Guzman
    Lostes, Julia
    Oliveira, Mafalda
    Mirallas, Oriol
    Oberoi, Arjun
    Pretelli, Giulia
    Ortega, Belen
    Granados, Raquel
    Giralt, Jordi
    Bescos, Coro
    Lorente, Juan
    Siurana, Sahyly
    Tabernero, Joseph
    Oaknin, Ana
    Felip, Enriqueta
    Garralda, Elena
    Brana, Irene
    [J]. RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S171 - S172
  • [39] The performance of model-based versus rule-based phase I clinical trials in oncologyA quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years
    E. M. J. van Brummelen
    A. D. R. Huitema
    E. van Werkhoven
    J. H. Beijnen
    J. H. M. Schellens
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43 : 235 - 242
  • [40] The performance of model-based versus rule-based phase I clinical trials in oncology A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years
    van Brummelen, E. M. J.
    Huitema, A. D. R.
    van Werkhoven, E.
    Beijnen, J. H.
    Schellens, J. H. M.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (03) : 235 - 242
12345